Bonnie Bassler Net Worth

The estimated Net Worth of Bonnie L Bassler is at least $3.15 Milion dollars as of 15 August 2024. Bonnie Bassler owns over 756 units of Regeneron Pharmaceuticals stock worth over $2,440,420 and over the last 8 years he sold REGN stock worth over $0. In addition, he makes $709,993 as Independent Director at Regeneron Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Bonnie Bassler REGN stock SEC Form 4 insiders trading

Bonnie has made over 21 trades of the Regeneron Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 756 units of REGN stock worth $280,778 on 15 August 2024.

The largest trade he's ever made was exercising 3,167 units of Regeneron Pharmaceuticals stock on 8 September 2022 worth over $1,231,931. On average, Bonnie trades about 474 units every 26 days since 2016. As of 15 August 2024 he still owns at least 2,138 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Bonnie Bassler stock trades at the bottom of the page.

Bonnie Bassler biography

Dr. Bonnie L. Bassler Ph.D. serves as Independent Director of the Company. She is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation, and the American Academy of Microbiology. She has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society of London, and the American Philosophical Society, and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award, and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her B.Sc. from the University of California, Davis, and her Ph.D. in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, California, before becoming a faculty member at Princeton University. Dr. Bassler served as a director of Sanofi from November 2014 to July 2016 and currently serves on the board of directors of Kaleido Biosciences, Inc. Dr. Bassler’s extensive research experience and her scientific and academic career and accomplishments, as well as her experience as a corporate director, led the board to conclude that Dr. Bassler should serve as a director.

What is the salary of Bonnie Bassler?

As the Independent Director of Regeneron Pharmaceuticals, the total compensation of Bonnie Bassler at Regeneron Pharmaceuticals is $709,993. There are 20 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.

How old is Bonnie Bassler?

Bonnie Bassler is 57, he's been the Independent Director of Regeneron Pharmaceuticals since 2016. There are 18 older and 5 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.

Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis a Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Complete history of Bonnie Bassler stock trades at Cidara Therapeutics Inc, Regeneron Pharmaceuticals, Royalty Pharma plc a Kaleido Biosciences Inc

Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:

• P. Roy Vagelos,
  Chairman of the Board, Director
• Leonard Schleifer,
  President, Chief Executive Officer, Director
• George Yancopoulos,
  President, Chief Scientific Officer, Director
• Marion McCourt,
  Senior Vice President - Commercial
• Andrew Murphy,
  Executive Vice President - Research
• Neil Stahl,
  Executive Vice President - Research and Development
• Robert Landry,
  Chief Financial Officer, Executive Vice President - Finance
• Daniel Van Plew,
  Executive Vice President, General Manager - Industrial Operations and Product Supply
• Dr. George D. Yancopoulos M.D., Ph.D.,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Dr. Leonard S. Schleifer M.D., Ph.D.,
  Founder, Pres, CEO & Director
• Dr. George D. Yancopoulos,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Robert E. Landry Jr.,
  Exec. VP of Fin. & CFO
• Daniel P. Van Plew,
  Exec. VP and GM of Industrial Operations & Product Supply
• Joseph J. LaRosa,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Andrew J. Murphy,
  Exec. VP of Research
• Arthur Ryan,
  Independent Director
• George Sing,
  Independent Director
• Christine Poon,
  Independent Director
• Michael Brown,
  Independent Director
• Huda Zoghbi,
  Independent Director
• Joseph Goldstein,
  Independent Director
• Bonnie Bassler,
  Independent Director
• N. Anthony Coles,
  Independent Director
• Marc Tessier-Lavigne,
  Independent Director
• Christopher Fenimore,
  Vice President, Controller
• Joseph LaRosa,
  Executive Vice President, General Counsel, Secretary
• Justin Holko,
  VP of Investor Relations
• Bob McCowan,
  Sr. VP of IT & Chief Information Officer
• Gerald Underwood,
  Sr. VP of Technical Operations
• Christopher R. Fenimore,
  Sr. VP, Head of Accounting & Controller
• Patrice Gilooly,
  Sr. VP of Quality Assurance & Operations
• Charles A Baker,
  Director
• Michael S Aberman,
  SVP Strategy Investor Relation
• Sanofi,
  
• Robert J Terifay,
  EVP Commercial
• Alfred G Gilman,
  Director
• Robert Alexander Ingram,
  Director
• Eric M Shooter,
  Director
• Murray A Goldberg,
  SVP Administration & Asst Secr
• Stuart Kolinski,
  SVP General Counsel and Secret
• Amerique Du Nord S.N.C. San...,
  
• Peter Dworkin,
  VP Investor Relations & Commun
• Randall Rupp,
  SVP, Manufuring Operations
• Pharma Ag Novartis,
  10% owner
• Hans Peter Guler,
  VP Clinical Programs
• William Roberts,
  VP Reg Dev & Med Safety
• Peter Powchik,
  SVP Clinical Development & Reg
• Douglas S Mc Corkle,
  VP Controller and Asst Treasur
• Craig B. Thompson,
  Director
• Kathryn Guarini,
  Director
• David P Schenkein,
  Director
• Jason Pitofsky,
  VP Controller